valproic acid has been researched along with Critical Illness in 14 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Both levocarnitine and lactulose, either alone or in combination, have been used for the treatment of hyperammonemia associated with valproic acid, however they have not been directly compared in the literature." | 8.02 | Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients. ( Cunningham, B; Fowler, M; Mullen, C; Nicholson, C, 2021) |
| "Valproic acid has been proposed as an alternative agent for treatment of agitation and delirium in the intensive care unit (ICU)." | 7.96 | Valproic Acid for the Management of Agitation and Delirium in the Intensive Care Setting: A Retrospective Analysis. ( Crowley, KE; Geiger, KL; Hacobian, G; Urben, L, 2020) |
| "Thrombocytopenia is a common laboratory abnormality among critically ill patients under neurological intensive care unit (NCU) care." | 5.56 | Thrombocytopenia during intravenous valproic acid therapy in the neurological intensive care unit. ( Chun, YI; Kim, DW; Kim, W; Lee, CH, 2020) |
| " Both levocarnitine and lactulose, either alone or in combination, have been used for the treatment of hyperammonemia associated with valproic acid, however they have not been directly compared in the literature." | 4.02 | Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients. ( Cunningham, B; Fowler, M; Mullen, C; Nicholson, C, 2021) |
| "Valproic acid has been proposed as an alternative agent for treatment of agitation and delirium in the intensive care unit (ICU)." | 3.96 | Valproic Acid for the Management of Agitation and Delirium in the Intensive Care Setting: A Retrospective Analysis. ( Crowley, KE; Geiger, KL; Hacobian, G; Urben, L, 2020) |
| "The patient's hypoalbuminemia probably explains the remarkably high free fraction of valproic acid." | 3.77 | High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy. ( de Maat, MM; Edelbroek, PM; van Leeuwen, HJ, 2011) |
| "Sixty critically ill pediatric patients receiving phenytoin for treatment of seizures in a large multidisciplinary intensive care unit." | 3.73 | Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. ( Dodson, B; McClain, CD; McManus, ML; Wolf, GK; Zurakowski, D, 2006) |
| " Additional research to define best practice for dosing and monitoring valproate and the relationship between free valproate concentrations and clinical or adverse effects in ICU patients is needed." | 2.55 | Valproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review. ( Fraser, GL; Gagnon, DJ; Hatton, C; May, T; Riker, RR; Seder, DB; Stokem, K, 2017) |
| "The aim of this review was to evaluate current literature for dosing recommendations for the use of antiepileptic medications in patients receiving renal replacement therapy (RRT)." | 2.53 | Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. ( Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016) |
| "Thrombocytopenia is a common laboratory abnormality among critically ill patients under neurological intensive care unit (NCU) care." | 1.56 | Thrombocytopenia during intravenous valproic acid therapy in the neurological intensive care unit. ( Chun, YI; Kim, DW; Kim, W; Lee, CH, 2020) |
| "Phenytoin has a narrow therapeutic index and the potential of under-treatment or toxicity." | 1.56 | A Novel Correction Equation Avoids High-Magnitude Errors in Interpreting Therapeutic Drug Monitoring of Phenytoin Among Critically Ill Patients. ( Barra, ME; Chung, DY; Phillips, KM; Rosenthal, ES, 2020) |
| "Specific treatment for hyperammonemia must be implemented promptly." | 1.48 | Valproate-induced hyperammonemia - uncovering an underlying inherited metabolic disorder: a case report. ( Lachmann, R; Mehta, S; Tayabali, S, 2018) |
| "Valproic acid (VPA) is a broad-spectrum antiepileptic drug used for a variety of neurologic disorders." | 1.43 | Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients. ( Cook, AM; Van Matre, ET, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Nicholson, C | 1 |
| Fowler, M | 1 |
| Mullen, C | 1 |
| Cunningham, B | 1 |
| De Fazio, C | 1 |
| Goffin, M | 1 |
| Franchi, F | 1 |
| Ferlini, L | 1 |
| Orinckx, C | 1 |
| Spadaro, S | 1 |
| Brasseur, A | 1 |
| Gaspard, N | 1 |
| Antonucci, E | 1 |
| Khattar, L | 1 |
| Peluso, L | 1 |
| Romeo, I | 1 |
| Creteur, J | 1 |
| Legros, B | 1 |
| Taccone, FS | 1 |
| Kim, DW | 1 |
| Kim, W | 1 |
| Lee, CH | 1 |
| Chun, YI | 1 |
| Barra, ME | 1 |
| Phillips, KM | 1 |
| Chung, DY | 1 |
| Rosenthal, ES | 1 |
| Crowley, KE | 1 |
| Urben, L | 1 |
| Hacobian, G | 1 |
| Geiger, KL | 1 |
| Gagnon, DJ | 4 |
| Fontaine, GV | 2 |
| Riker, RR | 4 |
| Fraser, GL | 4 |
| Mehta, S | 1 |
| Tayabali, S | 1 |
| Lachmann, R | 1 |
| Hatton, C | 2 |
| May, T | 2 |
| Seder, DB | 2 |
| Van Matre, ET | 1 |
| Cook, AM | 2 |
| Smetana, KS | 1 |
| Bastin, ML | 1 |
| Oyler, DR | 1 |
| Smith, KE | 1 |
| Miller, RR | 1 |
| Lerwick, PA | 1 |
| Lucas, FL | 1 |
| Dziodzio, JT | 1 |
| Sihler, KC | 1 |
| Stokem, K | 1 |
| de Maat, MM | 1 |
| van Leeuwen, HJ | 1 |
| Edelbroek, PM | 1 |
| Wolf, GK | 1 |
| McClain, CD | 1 |
| Zurakowski, D | 1 |
| Dodson, B | 1 |
| McManus, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for valproic acid and Critical Illness
| Article | Year |
|---|---|
Repurposing Valproate, Enteral Clonidine, and Phenobarbital for Comfort in Adult ICU Patients: A Literature Review with Practical Considerations.
Topics: Administration, Oral; Administration, Sublingual; Adult; Clonidine; Critical Illness; Drug Repositio | 2017 |
Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Topics: Acetamides; Acute Kidney Injury; Amines; Anticonvulsants; Carbamates; Critical Illness; Cyclohexanec | 2016 |
Valproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review.
Topics: Academic Medical Centers; Adult; Aged; Anticonvulsants; Critical Illness; Female; Humans; Intensive | 2017 |
11 other studies available for valproic acid and Critical Illness
| Article | Year |
|---|---|
Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients.
Topics: Carnitine; Cohort Studies; Critical Illness; Humans; Hyperammonemia; Lactulose; Retrospective Studie | 2021 |
Hyperammonemia during treatment with valproate in critically ill patients.
Topics: Aged; Critical Care; Critical Illness; Enzyme Inhibitors; Female; Humans; Hyperammonemia; Incidence; | 2022 |
Thrombocytopenia during intravenous valproic acid therapy in the neurological intensive care unit.
Topics: Administration, Intravenous; Aged; Anticonvulsants; Critical Illness; Dose-Response Relationship, Dr | 2020 |
A Novel Correction Equation Avoids High-Magnitude Errors in Interpreting Therapeutic Drug Monitoring of Phenytoin Among Critically Ill Patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Critical Care; Critical Illness; Drug Monitoring; F | 2020 |
Valproic Acid for the Management of Agitation and Delirium in the Intensive Care Setting: A Retrospective Analysis.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antipsychotic Agents; Benzodiazepines; Critical Care; C | 2020 |
Valproate-induced hyperammonemia - uncovering an underlying inherited metabolic disorder: a case report.
Topics: Anticonvulsants; Critical Illness; Dietary Proteins; Humans; Hyperammonemia; Male; Ornithine Carbamo | 2018 |
Free serum valproate concentration more reliable than total concentration in critically ill patients.
Topics: Aged; Aged, 80 and over; Critical Illness; Female; Humans; Male; Valproic Acid | 2016 |
Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients.
Topics: Adult; Anticonvulsants; Cohort Studies; Critical Illness; Dose-Response Relationship, Drug; Drug Adm | 2016 |
Valproate for agitation in critically ill patients: A retrospective study.
Topics: Adult; Aged; Analgesics, Opioid; Critical Illness; Delirium; Dexmedetomidine; Female; Fentanyl; GABA | 2017 |
High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy.
Topics: Anticonvulsants; Critical Illness; Female; Humans; Hypoalbuminemia; Middle Aged; Renal Replacement T | 2011 |
Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anticonvulsants; Blood Chemical Analysis; Cefazolin; Child | 2006 |